AJDRAJNR - American Journal of Neuroradiology

Published ahead of print on February 13, 2008
doi: 10.3174/ajnr.A0963
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajnr.A0963v1
29/3/419    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henson, J.W.
Right arrow Articles by Harris, G.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henson, J.W.
Right arrow Articles by Harris, G.J.

American Journal of Neuroradiology 29:419-424, March 2008
© 2008 American Society of Neuroradiology

Review Article

Brain Tumor Imaging in Clinical Trials

J.W. Hensona,b,c,d,e,f, S. Ulmera and G.J. Harrisc,d,f

a Stephen E. and Catherine Pappas Brain Tumor Imaging Research Program, Massachusetts General Hospital, Boston, Mass
b Division of Neuroradiology, Massachusetts General Hospital, Boston, Mass
c 3D Imaging Service, Massachusetts General Hospital, Boston, Mass
d Department of Radiology, Massachusetts General Hospital, Boston, Mass
e Neurology Service, Massachusetts General Hospital, Boston, Mass
f Harvard Medical School, Boston, Mass

Please address correspondence to John W. Henson, MD, Stephen E. and Catherine Pappas Brain Tumor Imaging Research Program, Massachusetts General Hospital, 55 Fruit St, Yawkey Nine East, Boston, MA 02114; e-mail: henson{at}helix.mgh.harvard.edu

SUMMARY: There are substantial challenges in the radiologic evaluation of tumor size during clinical trials, and it is important for neuroradiologists to have a firm understanding of these issues. This review will examine measurement approaches, response criteria, selection of lesions for measurement, technical imaging considerations, interval between tumor measurements and response confirmation, and validity of imaging as a measure of efficacy.




This article has been cited by other articles:


Home page
 JCOHome page
M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Chang, J. Clarke, and P. Wen
Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma
ASCO Educational Book, January 1, 2009; 2009(1): 107 - 111.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. S. Paulson and K. M. Schmainda
Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors
Radiology, November 1, 2008; 249(2): 601 - 613.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
Oncologist, September 1, 2008; 13(9): 978 - 992.
[Abstract] [Full Text] [PDF]


Copyright © 2009 by the American Society of Neuroradiology. Print ISSN: 0195-6108 Online ISSN: 1936-959X